RANDOMIZED, PLACEBO-CONTROLLED,DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287(AMG 888) IN COMBINATION WITHTRASTUZUMAB PLUS PACLITAXEL IN NEWLYDIAGNOSED HER2-POSITIVE METASTATICBREAST CANCER (MBC)

DAIICHI SANKYO PHARMA DEVELOPMENT,0 个研究点目标入组 0 人开始时间: 2013年8月22日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 100（—）
性别: Female

入选标准

•Subjects must satisfy all of the following criteria to be
•included in the study:
•1. Women ≥ 18 years old.
•2. Histologically or cytologically confirmed
•adenocarcinoma of the breast with metastatic
•disease and at least 1 measureable lesion per
•RECIST guidelines Version 1.1.
•3. Documented HER2+ disease as measured by
•fluorescence in situ hybridization (FISH) or
•immunohistochemistry (IHC) (3+).
•4. Eastern Cooperative Oncology Group (ECOG)
•performance status 0 or 1.
•5. Hematological function, as follows:
•-Absolute neutrophil count (ANC) ≥ 1.5 x
•- Platelet count ≥ 100 x 10^9/L
•- Hemoglobin ≥ 9 g/dL.
•6. Renal function, as follows:
•- Calculated creatinine clearance
•≥ 60 mL/min using the modified
•Cockroft-Gault equation.
•7. Hepatic function, as follows:
•- Aspartate aminotransferase (AST)
•≤ 2.5 x the upper limit of normal (ULN) (if
•liver metastases are present, < 5 x ULN)
•- Alanine aminotransferase (ALT)
•≤ 2.5 x ULN (if liver metastases are present,
•< 5 x ULN)
•- Alkaline phosphatase ≤ 2.0 x ULN (if bone
•or liver metastases are present, < 5 x ULN)
•- Bilirubin ≤ 1.5 x ULN.
•8. Prothrombin time (PT) and partial thromboplastin
•time (PTT) ≤ 1.5 x ULN.
•9. Availability of archived tumor sample or fresh
•tumor specimen (does not have to be provided by
•treatment start) to confirm HER2 status and for
•tumor biomarkers/mutation analysis.
•10. Subjects must be postmenopausal (no menstrual
•period for a minimum of 12 months) or surgically
•sterile, or must use maximally effective birth
•control during the period of therapy, and be willing
•to use contraception for 6 months following the last
•investigational drug dose and have a negative urine
•or serum pregnancy test upon entry into this study if
•subject is of childbearing potential. Partners of
•subjects must be surgically sterile or willing to use a
•double barrier contraception method upon
•enrollment, during the course of the study, and for
•6 months after the last investigational drug dose
•11. Subjects must be willing and able to comply with
•scheduled visits, treatment plan, laboratory tests,
另有 7 项未显示

排除标准

•Subjects who meet any of the following criteria will be
•disqualified from entering the study:
•1. Prior treatment for metastatic disease other than
•radiation therapy. Neoadjuvant/adjuvant therapy with paclitaxel, and/or docetaxel, and/or
•trastuzumab is allowed if completed more than 12
•months prior to relapse/progression.
•2. Clinically active brain metastases, defined as
•untreated symptomatic, or requiring therapy with
•steroids or anticonvulsants to control associated
•symptoms. Subjects with treated brain metastases
•that are no longer symptomatic and require no
•treatment with steroids or anticonvulsants may be
•included in the study if they have recovered from
•the acute toxic effect of radiotherapy.
•3. Left ventricular ejection fraction (LVEF) < 50%.
•History of LVEF decline to < 50% on prior
•trastuzumab therapy.
•4. Therapeutic or palliative radiation therapy or major
•surgery within 4 weeks before study drug treatment.
•5. History of other malignancies, except adequately
•treated nonmelanoma skin cancer, curatively treated
•in-situ cancer, or other solid tumors curatively
•treated with no evidence of disease for ≥ 5 years.
•6. Uncontrolled hypertension (diastolic blood pressure
•> 100 mmHg or systolic blood pressure
•> 140 mmHg). Use of antihypertensive
•medications is permissible to maintain blood
•pressure within the required parameters.
•7. Clinically significant electrocardiogram (ECG)
•changes that obscure the ability to assess the RR,
•PR, QT, QTc and QRS intervals. Subjects with left
•bundle branch block, atrial fibrillation and use of a
•cardiac pacemaker specifically will be excluded.
•8. Ascites or pleural effusion requiring chronic
•medical intervention.
•9. Pre-existing peripheral neuropathy > grade 1.
•10. Myocardial infarction, symptomatic congestive
•heart failure (CHF) (New York Heart Association
•> Class II), unstable angina, or unstable cardiac
•arrhythmia requiring medication within 1 year
•before enrollment.
•11. Use of cytochrome P450 (CYP) 3A4 (CYP3A4) or
•CYP2C8 inducers within 28 days prior to Day 1,
•use of CYP3A4 or CYP2C8 inhibitors within 14 days prior to Day 1, or concurrent use of CYP3A4 or CYP2C8 inducers or inhibitors.
•12. Use of amiodarone within 6 months prior to
•enrollment.
•13. Concurrent use of antiarrhythmic medications.
•14. Participated in clinical drug studies within 4 weeks
•(2 weeks for small molecule tyrosine kinase
•inhibitors; 6 weeks for mitomycin C and
另有 18 项未显示

研究者

发起方

DAIICHI SANKYO PHARMA DEVELOPMENT,

相似试验

进行中（未招募）

不适用

A Randomized Study comparing placebo and U3-1287 (AMG888) in combination with erlotinib in treatment of subjects with advanced non-small cell lung cancer who have progressed on at least one prior chemotherapyMedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Treatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy regimenMedDRA version: 14.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2010-021082-74-SIDAIICHI SANKYO DEVELOPMENT LTD.210

进行中（未招募）

不适用

A Randomized Study comparing placebo and U3-1287 (AMG888) incombination with erlotinib in treatment of subjects with advanced nonsmall cell lung cancer who have progressed on at least one priorchemotherapyTreatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy regimenMedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2010-021082-74-BGDAIICHI SANKYO DEVELOPMENT LTD.210

进行中（未招募）

不适用

A Randomized Study comparing placebo and U3-1287 (AMG888) incombination with erlotinib in treatment of subjects with advanced nonsmallcell lung cancer who have progressed on at least one priorchemotherapyTreatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy regimenMedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2010-021082-74-LTDAIICHI SANKYO DEVELOPMENT LTD.210

进行中（未招募）

1 期

A Randomized Study comparing placebo and U3-1287 (AMG888) in combination with erlotinib in treatment of subjects with advanced non-small cell lung cancer who have progressed on at least one prior chemotherapyTreatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy regimenMedDRA version: 14.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2010-021082-74-GBDAIICHI SANKYO DEVELOPMENT LTD.222

进行中（未招募）

不适用

A Randomized Study comparing placebo and U3-1287 (AMG888) in combination with erlotinib in treatment of subjects with advanced non-small cell lung cancer who have progressed on at least one prior chemotherapyTreatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy regimenMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2010-021082-74-ATDAIICHI SANKYO DEVELOPMENT LTD.210